Holen Sie sich die Stockscreener-App
2.11
3.94%
0.08
Handel nachbörslich:
2.09
-0.02
-0.95%
Schlusskurs vom Vortag:
$2.03
Offen:
$2.02
24-Stunden-Volumen:
215.04K
Relative Volume:
0.15
Marktkapitalisierung:
$19.05M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.16M
KGV:
-6.2059
EPS:
-0.34
Netto-Cashflow:
$-39.49M
1W Leistung:
-6.64%
1M Leistung:
-16.10%
6M Leistung:
-33.44%
1J Leistung:
-49.76%
1-Tages-Spanne:
$2.02
$2.13
1-Wochen-Bereich:
$1.83
$2.28
52-Wochen-Spanne:
$1.83
$9.19
Dare Bioscience Inc Stock (DARE) Company Profile
Firmenname
Dare Bioscience Inc
Sektor
Branche
Telefon
858-926-7655
Adresse
3655 NOBEL DRIVE, SAN DIEGO, CA
Vergleichen Sie DARE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
2.11 | 17.44M | 0 | -30.16M | -39.49M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Dare Bioscience Inc Aktie (DARE) Neueste Nachrichten
Dare Bioscience Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Dare Bioscience (DARE) down more than 70% since Jul 14 - AInvest
Daré Bioscience to Host Second Quarter 2025 Financial - GlobeNewswire
Daré Bioscience to Present Q2 Results: Women's Health Pipeline and Financial Updates Coming August 14 - Stock Titan
Dare Bioscience shares fall 1.61% premarket after launching consumer awareness campaign for DARE to PLAY Sildenafil Cream. - AInvest
Dare Bioscience shares fall 2.75% intraday after launching consumer awareness campaign for DARE to PLAY Sildenafil Cream. - AInvest
Daré Bioscience and Rosy Wellness Launch First Phase of - GlobeNewswire
Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream - The Manila Times
Revolutionary Female Viagra Cream DARE to PLAY Gets Major Launch Campaign Before Q4 Release - Stock Titan
Daré Bioscience Meets Nasdaq Equity Requirement - TipRanks
Daré Bioscience Inc. Stock Analysis and ForecastFree Bull & Bear Market Updates - Autocar Professional
UPDATEDaré Bioscience to Host August 6 Webinar: The DARE - GlobeNewswire
Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ DifferenceThe Sildenafil Cream That Raises the Bar - GlobeNewswire
Revolutionary Female Viagra Cream: First-Ever FDA-Approved Sildenafil Treatment for Women Coming This Year - Stock Titan
Daré Bioscience Reports Positive Contraception Trial Results as Smart Drug Delivery Platform Shows Broader Potential - Femtech Insider
Hold Rating on Daré Bioscience: Balancing Promising Product Development with Financial Uncertainties - TipRanks
Dare Bioscience stock holds Buy rating at H.C. Wainwright on positive trial data - Investing.com Canada
Small Healthcare Stocks Enjoy Big Wins On Deal News - Finimize
3 Penny Stocks to Watch Now, 7/15/25 - TipRanks
Daré Bioscience reports positive interim results for hormone-free contraceptive - Investing.com Australia
US Stocks End Higher Amid Tariff Concerns: Investor Sentiment Improves, Fear & Greed Index Remains In 'Extreme Greed' Zone - Benzinga
Dare Bioscience Surges to 200th in Market Rankings with $47.4 Million Turnover - AInvest
Douglas Tsao Recommends ‘Buy’ for Daré Bioscience: Ovaprene’s Promising Potential and Financial Prospects - TipRanks
Crude Oil Moves Lower; Daré Bioscience Shares Jump - inkl
Dare reports interim safety, efficacy results from Phase 3 trial of Ovaprene - TipRanks
Daré Bioscience stock soars after positive interim Phase 3 contraceptive results - Investing.com India
Daré Bioscience Soars 250% on Positive Ovaprene Trial Data - Wall Street Pit
Dare Bioscience’s Unforeseen Stock Skyward Leap - StocksToTrade
US Stocks Edge Lower; Fastenal Posts Upbeat Earnings - Benzinga
Dare Bioscience Reflects on Grant Milestone - timothysykes.com
Daré Bioscience reports positive interim results for hormone-free contraceptive By Investing.com - Investing.com South Africa
Why Is Daré Bioscience Stock (DARE) Up 240% Today? - TipRanks
Dare Bioscience Announces Positive Results From Hormone-Free Contraceptive Trial; Shares Surge - MarketScreener
Daré Bioscience Announces Positive Phase 3 Trial Results - TipRanks
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive - The Manila Times
Daré Bioscience Announces Positive Interim Results from Phase 3 Trial of Hormone-Free Contraceptive Ovaprene® - Quiver Quantitative
Dare Bioscience Plunges 11.33% Amid Market Shifts - AInvest
Daré Bioscience receives $6 million installment for contraceptive device - Investing.com Australia
Daré Bioscience Receives $6 Million Non-Dilutive Grant - GlobeNewswire
Dare Bioscience Sees Stock Surge Amid Strategic Collaborations - StocksToTrade
Daré Bioscience receives $6 million installment for contraceptive device By Investing.com - Investing.com South Africa
Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders - GlobeNewswire
Daré's Smart Drug Delivery Platform Secures $6M Grant, Eyes Expansion into $B Obesity Market - Stock Titan
Dare Bioscience shareholders approve board nominees and stock plan amendment - Investing.com Nigeria
Daré Bioscience Stockholder Meeting Approves Key Proposals - TipRanks
Finanzdaten der Dare Bioscience Inc-Aktie (DARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):